Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Sana Biotechnology, Inc.NASDAQ: SANA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$44.82M, compared with -$45.74M a year earlier. Trailing-twelve-month EBITDA was -$187.06M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +7.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$44.82M+19.6% QoQ
- Last fiscal yearDec 2025
- -$231.42M+7.2% YoY
- LTMMar 2026
- -$187.06M+2.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.0% | +100.0% | +98.0 pp |
| 1 year | +7.2% | +100.0% | +92.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (231.42M) USD
- Year-over-year change
- +7.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (231.42M) | +7.2% |
| FY2024 | 2024-12-31 | (249.37M) | +3.6% |
| FY2023 | 2023-12-31 | (258.7M) | -1.9% |
| FY2022 | 2022-12-31 | (253.85M) | +26.4% |
| FY2021 | 2021-12-31 | (344.86M) | — |
EBITDA vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 EBITDA of -$187.06M is the 8th highest of the 11 companies compared; the peer median is -$103.66M.
- Its year-over-year change of +2.3% is the 7th highest of 11, against a peer median of +14.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $99.55M | +154.3% | — | 7.3% | |
| LTM Mar 2026 | -$5.48M | +4.6% | — | 23.7% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Jun 2026 | -$63.18M | +83.2% | — | 40.5% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$187.06M | +2.3% | — | — | |
| LTM Mar 2026 | -$220.73M | -23.8% | — | — | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| Peer median (excluding SANA) | -$103.66M | +14.0% | — | 89.7% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| Weighted Avg Shares | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
| Weighted Avg Shares (Diluted) | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.